Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of CEP-33457 in SLE
NCT01240694Phase 3Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Dec 2010
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of foralumab in systemic lupus erythematosus (SLE), sponsored by Cephalon, Inc.. Started Dec 2010; status: terminated.
02
Drugs
foralumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01240694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01240694.